PAB Stock Overview
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.02|
|52 Week High||AU$0.046|
|52 Week Low||AU$0.019|
|1 Month Change||-25.93%|
|3 Month Change||-4.76%|
|1 Year Change||-51.22%|
|3 Year Change||-4.76%|
|5 Year Change||33.34%|
|Change since IPO||-96.85%|
Recent News & Updates
Will Patrys (ASX:PAB) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|PAB||AU Biotechs||AU Market|
Return vs Industry: PAB underperformed the Australian Biotechs industry which returned -5.6% over the past year.
Return vs Market: PAB underperformed the Australian Market which returned -10.8% over the past year.
|PAB Average Weekly Movement||9.3%|
|Biotechs Industry Average Movement||10.2%|
|Market Average Movement||9.4%|
|10% most volatile stocks in AU Market||16.5%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: PAB is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: PAB's weekly volatility (9%) has been stable over the past year.
About the Company
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer.
Patrys Fundamentals Summary
|PAB fundamental statistics|
Is PAB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PAB income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.0033|
|Net Profit Margin||-203.40%|
How did PAB perform over the long term?See historical performance and comparison
Is PAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PAB?
Other financial metrics that can be useful for relative valuation.
|What is PAB's n/a Ratio?|
Price to Sales Ratio vs Peers
How does PAB's PS Ratio compare to its peers?
|PAB PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
CYP Cynata Therapeutics
Price-To-Sales vs Peers: PAB is expensive based on its Price-To-Sales Ratio (12.3x) compared to the peer average (10x).
Price to Earnings Ratio vs Industry
How does PAB's PE Ratio compare vs other companies in the AU Biotechs Industry?
Price-To-Sales vs Industry: PAB is good value based on its Price-To-Sales Ratio (12.3x) compared to the Australian Biotechs industry average (19.7x)
Price to Sales Ratio vs Fair Ratio
What is PAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||12.3x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate PAB's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of PAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate PAB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PAB's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Patrys forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Patrys has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Patrys performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PAB is currently unprofitable.
Growing Profit Margin: PAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PAB is unprofitable, and losses have increased over the past 5 years at a rate of 37.9% per year.
Accelerating Growth: Unable to compare PAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: PAB has a negative Return on Equity (-50.5%), as it is currently unprofitable.
Discover strong past performing companies
How is Patrys's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: PAB's short term assets (A$13.5M) exceed its short term liabilities (A$542.8K).
Long Term Liabilities: PAB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: PAB is debt free.
Reducing Debt: PAB has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PAB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PAB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 37.6% each year
Discover healthy companies
What is Patrys's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Patrys Dividend Yield vs Market|
|Market Bottom 25% (AU)||2.8%|
|Market Top 25% (AU)||7.2%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Patrys)||n/a|
Notable Dividend: Unable to evaluate PAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PAB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PAB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. James A. Campbell, BSc(Hons), PhD, MBA, GAICD, serves as Chief Executive Officer and Managing Director for Patrys Limited since April 13, 2015. Dr. Campbell serves as Principal of Gemini Biotechnology....
CEO Compensation Analysis
|James Campbell's Compensation vs Patrys Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||AU$718k||AU$327k|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||AU$601k||AU$325k|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||AU$434k||AU$318k|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||AU$504k||AU$305k|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||n/a||n/a|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||AU$399k||AU$280k|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||n/a||n/a|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||AU$338k||AU$280k|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||n/a||n/a|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||AU$220k||AU$218k|
Compensation vs Market: James's total compensation ($USD462.59K) is above average for companies of similar size in the Australian market ($USD274.64K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
Experienced Management: PAB's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Experienced Board: PAB's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|08 Apr 22||SellAU$776,353||Mason Stevens Limited||Company||22,426,656||AU$0.035|
|30 Mar 22||BuyAU$92,487||Mason Stevens Limited||Company||2,245,650||AU$0.041|
|06 Dec 21||SellAU$81,569||Macquarie Investment Management Limited||Company||2,039,214||AU$0.04|
|23 Nov 21||BuyAU$5,064||Macquarie Investment Management Limited||Company||129,661||AU$0.039|
|08 Nov 21||BuyAU$2,465,011||Macquarie Investment Management Limited||Company||70,428,571||AU$0.035|
|05 Nov 21||SellAU$0||Macquarie Investment Management Limited||Company||1,581,169||AU$0.05|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Patrys Limited's employee growth, exchange listings and data sources
- Name: Patrys Limited
- Ticker: PAB
- Exchange: ASX
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$41.140m
- Shares outstanding: 2.06b
- Website: https://www.patrys.com
- Patrys Limited
- 100 Albert Road
- Level 4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PAB||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jul 2007|
|PATL.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jul 2007|
|PAB||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jul 2007|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/01 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.